# Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa

> **NCT05874310** · EARLY_PHASE1 · RECRUITING · sponsor: **Frontera Therapeutics** · enrollment: 18 (estimated)

## Conditions studied

- X-Linked Retinitis Pigmentosa

## Interventions

- **GENETIC:** FT-002

## Key facts

- **NCT ID:** NCT05874310
- **Lead sponsor:** Frontera Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-01
- **Primary completion:** 2023-10-31
- **Final completion:** 2027-11-01
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2023-05-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05874310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05874310, "Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05874310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*